Dr. Rhonda Bohn
ScD, MPH, FISPE
Biography
(Pharmaco)-Epidemiologist with over 25 years of experience in the health care environment including clinical drug research, drug safety, health outcomes, database studies and other observational research.
Thorough understanding of epidemiology, health economics, outcomes research, and risk management. Global experience with study design, protocol development, study implementation and report/manuscript writing.
Key Publications
-
Bohn RL, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol 2018 Mar-Apr;36(2):263-274.
-
Gagne JJ, Rassen JA, Choudry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf 2014;37(3):151-161.
-
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc 2013;2(4):e000208.
-
Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21(12):1350-1358.
-
Bykov K, Bohn R, Ewenstein BM, et al. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors. Thromb Haemost 2017;117(12): 2267-2273.
Key Institutions
-
Bohn Epidemiology
LLC (2011-2024)
Boston, MA USA
Current Positions/Chairs
-
Self-employed consultant in Epidemiology.
-
Member
IPSG Access Expert Working Group
Research Interests
-
Pharmacoepidemiology
-
Drug Safety
-
Evidence-Based Medicine
-
Health Outcomes
-
Therapeutic areas of interest include rare diseases, coagulation disorders, neurodegenerative disorders, neuromuscular diseases, pulmonary disease, and mental health, including dementia and Alzheimer’s disease
Achievements
-
Received her MPH in Chronic Disease Epidemiology from Yale University and ScD in Epidemiology from Harvard University (focus on pharmacoepidemiology).
-
Serves on Advisory Boards and Steering Committees for large-scale and multi-database studies representing clients and Medical Society Organizations
-
Authored over 50 articles published in peer-reviewed journals and is a reviewer for many journals including Pharmacoepidemiology and Drug Safety, the Journal of Managed Care Pharmacy, Drug Safety, Thrombosis and Haemostasis, Pediatrics, and Haemophilia.
-
Served on the Editorial Board for Pharmacoepidemiology and Drug Safety from 2017-2018 and is an active member and Fellow of the International Society for Pharmacoepidemiology (ISPE) and served on its Board from 2014–2016.
Publications
Challenges associated with access to recently developed hemophilia treatments in routine care – healthcare professionals’ perspectives.
Authors
Berger K, O’Rourke RH, Matteo Nicola DD, Batorova A, Kavakli K, Mannuccio PM, Wolfgang Schramm W, Rhonda BL, Aledort L on behalf of the International Prophylaxis Study Group.
Citation
Hematologica. 2024 Mar 1; 110(3):673-682. DOI: 10.3324/haematol.2024.285647
Are all licensed hemostatic agents for hemophilia therapy accessible to patients? Letter to the Editor
Authors
Berger K, Batorova A, Bohn RL, di Minno M, Mannucci P, Kavakli K, Schramm W, Aledort L on behalf of the International Prophylaxis Study Group
Citation
Haemophilia. 2022; 28:e256–e258. DOI: 10.1111/hae.14660
Hemophilia Prophylaxis: How can we justify the costs?
Authors
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.
Citation
Haemophilia 2012 Sept; 18 (5): 680-684.